Kolor Bio - Genetics Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 24-10-2024
- Paid Up Capital ₹ 1.20 M
as on 24-10-2024
- Company Age 15 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.23 Cr
as on 24-10-2024
- Revenue 9.03%
(FY 2023)
- Profit 24.23%
(FY 2023)
- Ebitda -34.85%
(FY 2023)
- Net Worth 9.07%
(FY 2023)
- Total Assets 31.55%
(FY 2023)
About Kolor Bio - Genetics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.20 M.
The company currently has active open charges totaling ₹1.23 Cr.
Amit Jain, Kumarpal Jain, and Kunal Jain serve as directors at the Company.
- CIN/LLPIN
U24100MH2009PTC191903
- Company No.
191903
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Apr 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Kolor Bio - Genetics Private Limited offer?
Kolor Bio - Genetics Private Limited offers a wide range of products and services, including Leather Bags, Leather Handbag, Fashion Leather Handbag.
Who are the key members and board of directors at Kolor Bio - Genetics?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amit Jain  | Director | 21-Apr-2009 | Current |
| Kumarpal Jain | Director | 26-Nov-2009 | Current |
| Kunal Jain | Director | 27-Dec-2009 | Current |
Financial Performance of Kolor Bio - Genetics.
Kolor Bio - Genetics Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 9.03% increase. The company also saw a substantial improvement in profitability, with a 24.23% increase in profit. The company's net worth moved up by a moderate rise of 9.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kolor Bio - Genetics?
In 2023, Kolor Bio - Genetics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Kumar Brothers Pharma Private LimitedActive 19 years 9 monthsKumarpal Jain and Kunal Jain are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Ing Vysya Bank Limited Creation Date: 27 Jul 2011 | ₹7.50 M | Open |
Bank Of India Creation Date: 14 Oct 2009 | ₹4.80 M | Open |
How Many Employees Work at Kolor Bio - Genetics?
Unlock and access historical data on people associated with Kolor Bio - Genetics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kolor Bio - Genetics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kolor Bio - Genetics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
